A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity

Paused · Phase 2 · Has a placebo group

Conditions studied: Obesity, Insulin Resistance

In brief

Many metabolic complications of obesity are a consequence of abnormal responses of the liver, muscle, and fat to insulin actions. Fenretinide may improve the effects of insulin, preventing metabolic complications.

Key facts

Study ID

NCT00546455

Run by

University of California, San Diego

People needed

21

Starts

2007-12-01

Expected to finish

2099-01-01

Last updated by the study team

2021-02-10

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• BMI >30

You may not qualify if…

• Diabetes Requiring Medication
• Poorly Controlled Co-Morbidities

Where it is running

• University of California at San Diego Hospitals — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.